Human-IgG-Neutralizing Monoclonal Antibodies Block the SARS-CoV-2 Infection
Jinkai Wan, Shenghui Xing, Longfei Ding, Yongheng Wang, Chenjian Gu, Yanling Wu, Bowen Rong, Cheng Li, Siqing Wang, Kun Chen, Chenxi He, Dandan Zhu, Songhua Yuan, Chengli Qiu, Chen Zhao, Lei Nie, Zhangzhao Gao, Jingyu Jiao, Xiaoyan Zhang, Xiangxi Wang, Tianlei Ying, Haibin Wang, Youhua Xie, Yanan Lu, Jianqing Xu, Fei Lan
Abstract
of 1.75 nM. Through epitope mapping, we find three main epitopes in RBD recognized by these antibodies, and epitope-B antibody 553-15 could substantially enhance the neutralizing abilities of most of the other antibodies. We also find that 515-5 could cross neutralize the SARS-CoV pseudovirus. Altogether, our study provides 11 potent human neutralizing antibodies for COVID-19 as therapeutic candidates.
Topics & Concepts
EpitopeAntibodyMonoclonal antibodyVirologyNeutralizing antibodySevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)AntigenIC50Coronavirus disease 2019 (COVID-19)Epitope mappingConformational epitopeChemistryBiologyImmunologyMedicineDiseaseIn vitroInfectious disease (medical specialty)BiochemistryPathologySARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research Studiesvaccines and immunoinformatics approaches